News>Press Releases
Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel® and Seroquel XR®
June 01,2020

Luye Pharma Group (Luye Pharma) today held a special signing ceremony as part of the “We Care About Mental Health” initiative, marking the start of three new strategic partnerships across the region. As part of the initiative, Luye Pharma granted Alvogen Korea Co. Ltd. (Alvogen Korea), Zuellig Pharma Ltd. (Zuellig Pharma) and DKSH (Thailand) Ltd. (DKSH) exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand. Following the signing, the parties came together to issue a call for action as part of the “We Care About Mental Health” initiative, raising awareness and supporting patients, physicians and health systems in overcoming the huge unmet needs. This is especially timely against the challenging backdrop of the COVID-19 pandemic.
 

Luye Pharma signs agreements with partners
(Upper left to right: Dr. Yehong Zhang, President of Luye Pharma (International); Justin Lee, Country Manager of Alvogen Korea;
Lower left to right: Andi Umbricht, Chief Executive of Zuellig Pharma Hong Kong & Macau; Bijay Singh, Global Head of Business Unit Healthcare of DKSH)

Mental illnesses such as schizophrenia, bipolar disorder, depression, and anxiety present a major challenge to patients, physicians and healthcare systems in all countries. According to WHO statistics, the lifetime prevalence of schizophrenia is generally reported to affect around 1% of the world’s population, while the prevalence of bipolar disorder is reported to affect 2%-3%, and as much as 5% in some countries and regions. With the number of those affected worldwide expected to continue to grow over time, left untreated, both of these illnesses have the potential to do serious harm to patients and society. Schizophrenia patients have been found to have a higher overall mortality rate, two to three times as high as the general population, with life expectancy reduced by 10–20 years. The incidence of death by suicide among patients with bipolar disorder is high and can be more than 20 times higher than in the general population, particularly when untreated.

The devastating impact to sufferers and their loved ones is further exacerbated by the current COVID-19 pandemic.

The time to act is now. “We Care About Mental Health” is an initiative designed to raise awareness of the importance of mental health issues faced by society today, and intended to reach participants across multiple regions.

Luye Pharma together with the partners are committed to organizing a series of online and offline lectures hosted by experts in the field of mental health, helping to educate the public and further raise awareness of matters related to mental illness.

Luye Pharma and partners launch the “We Care About Mental Health” initiative
(Upper left to right: Andy Siow, APAC Regional Director of Luye Pharma (International); Justin Lee, Country Manager of Alvogen Korea;
Lower left to right: Andi Umbricht, Chief Executive of Zuellig Pharma Hong Kong & Macau; John Clare, Vice President Healthcare of DKSH Thailand & Indochina)

“Mental health is a serious global public health challenge that requires a sustained and united response from us all”, said Andy Siow, APAC Regional Director of Luye Pharma (International). “By partnering with three outstanding organizations in the region, we are confident that the ‘We Care About Mental Health’ initiative will help to increase understanding and awareness of mental health issues. It will also provide insights on the available treatment options and emphasize how important it is for sufferers to seek treatment.”

News>Press Releases
Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel® and Seroquel XR®
June 01,2020

Luye Pharma Group (Luye Pharma) today held a special signing ceremony as part of the “We Care About Mental Health” initiative, marking the start of three new strategic partnerships across the region. As part of the initiative, Luye Pharma granted Alvogen Korea Co. Ltd. (Alvogen Korea), Zuellig Pharma Ltd. (Zuellig Pharma) and DKSH (Thailand) Ltd. (DKSH) exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand. Following the signing, the parties came together to issue a call for action as part of the “We Care About Mental Health” initiative, raising awareness and supporting patients, physicians and health systems in overcoming the huge unmet needs. This is especially timely against the challenging backdrop of the COVID-19 pandemic.
 

Luye Pharma signs agreements with partners
(Upper left to right: Dr. Yehong Zhang, President of Luye Pharma (International); Justin Lee, Country Manager of Alvogen Korea;
Lower left to right: Andi Umbricht, Chief Executive of Zuellig Pharma Hong Kong & Macau; Bijay Singh, Global Head of Business Unit Healthcare of DKSH)

Mental illnesses such as schizophrenia, bipolar disorder, depression, and anxiety present a major challenge to patients, physicians and healthcare systems in all countries. According to WHO statistics, the lifetime prevalence of schizophrenia is generally reported to affect around 1% of the world’s population, while the prevalence of bipolar disorder is reported to affect 2%-3%, and as much as 5% in some countries and regions. With the number of those affected worldwide expected to continue to grow over time, left untreated, both of these illnesses have the potential to do serious harm to patients and society. Schizophrenia patients have been found to have a higher overall mortality rate, two to three times as high as the general population, with life expectancy reduced by 10–20 years. The incidence of death by suicide among patients with bipolar disorder is high and can be more than 20 times higher than in the general population, particularly when untreated.

The devastating impact to sufferers and their loved ones is further exacerbated by the current COVID-19 pandemic.

The time to act is now. “We Care About Mental Health” is an initiative designed to raise awareness of the importance of mental health issues faced by society today, and intended to reach participants across multiple regions.

Luye Pharma together with the partners are committed to organizing a series of online and offline lectures hosted by experts in the field of mental health, helping to educate the public and further raise awareness of matters related to mental illness.

Luye Pharma and partners launch the “We Care About Mental Health” initiative
(Upper left to right: Andy Siow, APAC Regional Director of Luye Pharma (International); Justin Lee, Country Manager of Alvogen Korea;
Lower left to right: Andi Umbricht, Chief Executive of Zuellig Pharma Hong Kong & Macau; John Clare, Vice President Healthcare of DKSH Thailand & Indochina)

“Mental health is a serious global public health challenge that requires a sustained and united response from us all”, said Andy Siow, APAC Regional Director of Luye Pharma (International). “By partnering with three outstanding organizations in the region, we are confident that the ‘We Care About Mental Health’ initiative will help to increase understanding and awareness of mental health issues. It will also provide insights on the available treatment options and emphasize how important it is for sufferers to seek treatment.”